title: LXR agonism inhibits metastatic melanoma through activation of ApoE.
abstract: Nuclear hormone receptor targeting suppresses melanoma progression in diverse preclinical models.
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001057:Apolipoproteins E / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D000071518:Liver X Receptors; D008545:Melanoma / Q000188:drug therapy*; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D057093:Orphan Nuclear Receptors / Q000819:agonists*
chemical_list: D000970:Antineoplastic Agents; D001057:Apolipoproteins E; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors